<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35868251</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1948-7193</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>15</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>ACS chemical neuroscience</Title><ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation></Journal><ArticleTitle>Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>2252</StartPage><EndPage>2260</EndPage><MedlinePgn>2252-2260</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.2c00261</ELocationID><Abstract><AbstractText>Polypharmacology is a new trend in amyotrophic lateral sclerosis (ALS) therapy and an effective way of addressing a multifactorial etiology involving excitotoxicity, mitochondrial dysfunction, oxidative stress, and microglial activation. Inspired by a reported clinical trial, we converted a riluzole (<b>1</b>)-rasagiline (<b>2</b>) combination into single-molecule multi-target-directed ligands. By a ligand-based approach, the highly structurally integrated hybrids <b>3</b>-<b>8</b> were designed and synthesized. Through a target- and phenotypic-based screening pipeline, we identified hit compound <b>6</b>. It showed monoamine oxidase A (MAO-A) inhibitory activity (IC<sub>50</sub> = 6.9 &#x3bc;M) rationalized by <i>in silico</i> studies as well as <i>in vitro</i> brain permeability. By using neuronal and non-neuronal cell models, including ALS-patient-derived cells, we disclosed for <b>6</b> a neuroprotective/neuroinflammatory profile similar to that of the parent compounds and their combination. Furthermore, the unexpected MAO inhibitory activity of <b>1</b> (IC<sub>50</sub> = 8.7 &#x3bc;M) might add a piece to the puzzle of its anti-ALS molecular profile.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albertini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salerno</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0300-9062</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atzeni</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uliassi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0990-2532</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massenzio</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruca</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6537-552X</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze della Salute, Universit&#xe0; "Magna Gr&#xe6;cia" di Catanzaro, Campus "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Net4Science Academic Spin-Off, Universit&#xe0; "Magna Gr&#xe6;cia" di Catanzaro, Campus "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0680-7097</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze della Salute, Universit&#xe0; "Magna Gr&#xe6;cia" di Catanzaro, Campus "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Net4Science Academic Spin-Off, Universit&#xe0; "Magna Gr&#xe6;cia" di Catanzaro, Campus "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecava</LastName><ForeName>Marko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Filomena S G</ForeName><Initials>FSG</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CNC), Centre for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mitotag Lda, Biocant Park, 3060-197 Cantanhede, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mena</LastName><ForeName>D&#xe9;bora</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CNC), Centre for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alem&#xe3;o - P&#xf3;lo II, Rua D. Francisco de Lemos, 3030-789 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CNC), Centre for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit for Sport and Physical Activity (CIDAF), Faculty of Sport Science and Physical Education (FCDEF-UC), University of Coimbra, 3040-248 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Ana I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CNC), Centre for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alem&#xe3;o - P&#xf3;lo II, Rua D. Francisco de Lemos, 3030-789 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavarria</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bissaro</LastName><ForeName>Maicol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7514-3802</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Federico</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2800-5287</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalluto</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soukup</LastName><ForeName>Ond&#x159;ej</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6376-8701</Identifier><AffiliationInfo><Affiliation>Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borges</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1050-2402</Identifier><AffiliationInfo><Affiliation>CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcaro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze della Salute, Universit&#xe0; "Magna Gr&#xe6;cia" di Catanzaro, Campus "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Net4Science Academic Spin-Off, Universit&#xe0; "Magna Gr&#xe6;cia" di Catanzaro, Campus "S. Venuta", Viale Europa, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0330-482X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Paulo J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology (CNC), Centre for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alem&#xe3;o - P&#xf3;lo II, Rua D. Francisco de Lemos, 3030-789 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Men&#xe9;ndez</LastName><ForeName>Jos&#xe8; C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-0560-8416</Identifier><AffiliationInfo><Affiliation>Department of Chemistry in Pharmaceutical Sciences, Organic and Medicinal Chemistry Unit, Faculty of Pharmacy, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolognesi</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-1289-5361</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Neurosci</MedlineTA><NlmUniqueID>101525337</NlmUniqueID><ISSNLinking>1948-7193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">MAO</Keyword><Keyword MajorTopicYN="N">MTDLs</Keyword><Keyword MajorTopicYN="N">Polypharmacology</Keyword><Keyword MajorTopicYN="N">benzothiazoles</Keyword><Keyword MajorTopicYN="N">rasagiline</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword></KeywordList><CoiStatement>The authors declare no
competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35868251</ArticleId><ArticleId IdType="pmc">PMC9354084</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.2c00261</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan M. C.; Vucic S.; Cheah B. C.; Turner M. R.; Eisen A.; Hardiman O.; Burrell J. R.; Zoing M. C. Amyotrophic Lateral Sclerosis. Lancet 2011, 377 (9769), 942&#x2013;955. 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A.; Palomo Ruiz M. D.; Perez D. I.; Gil C. Drugs In Clinical Development For The Treatment Of Amyotrophic Lateral Sclerosis. Expert Opin. Invest. Drugs 2017, 26 (4), 403&#x2013;414. 10.1080/13543784.2017.1302426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1302426</ArticleId><ArticleId IdType="pubmed">28277881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. ALS Antisense Drug Falters In Phase III. Nat. Rev. Drug Discovery 2021, 20 (12), 883&#x2013;885. 10.1038/d41573-021-00181-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00181-w</ArticleId><ArticleId IdType="pubmed">34716445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-C&#xe1;mara O.; Arribas M.; Wells G.; Morales-Tenorio M.; Mart&#xed;n-Requero &#xc1;.; Porras G.; Mart&#xed;nez A.; Giorgi G.; L&#xf3;pez-Alvarado P.; Lastres-Becker I.; et al. Multitarget Hybrid Fasudil Derivatives As A New Approach To The Potential Treatment Of Amyotrophic Lateral Sclerosis. J. Med. Chem. 2022, 65 (3), 1867&#x2013;1882. 10.1021/acs.jmedchem.1c01255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01255</ArticleId><ArticleId IdType="pmc">PMC9132363</ArticleId><ArticleId IdType="pubmed">34985276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli A.; Bolognesi M. L.; Minarini A.; Rosini M.; Tumiatti V.; Recanatini M.; Melchiorre C. Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases. J. Med. Chem. 2008, 51 (3), 347&#x2013;372. 10.1021/jm7009364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm7009364</ArticleId><ArticleId IdType="pubmed">18181565</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhasmana S.; Dhasmana A.; Narula A. S.; Jaggi M.; Yallapu M. M.; Chauhan S. C. The Panoramic View Of Amyotrophic Lateral Sclerosis: A Fatal Intricate Neurological Disorder. Life Sci. 2022, 288, 120156.10.1016/j.lfs.2021.120156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.120156</ArticleId><ArticleId IdType="pubmed">34801512</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S.; Reuter A.; Malessa S.; Blaugrund E.; Ludolph A. C. Rasagiline Alone And In Combination With Riluzole Prolongs Survival In An ALS Mouse Model. J. Neurol. 2004, 251 (9), 1080&#x2013;1084. 10.1007/s00415-004-0481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0481-5</ArticleId><ArticleId IdType="pubmed">15372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A. C.; Schuster J.; Dorst J.; Dupuis L.; Dreyhaupt J.; Weishaupt J. H.; Kassubek J.; Weiland U.; Petri S.; Meyer T.; et al. Safety And Efficacy Of Rasagiline As An Add-On Therapy To Riluzole In Patients With Amyotrophic Lateral Sclerosis: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 2 Trial. Lancet Neurol. 2018, 17 (8), 681&#x2013;688. 10.1016/S1474-4422(18)30176-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30176-5</ArticleId><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama W.; Youdim M. B.; Naoi M. Antiapoptotic Properties Of Rasagiline, N-Propargylamine-1(R)-Aminoindan, And Its Optical (S)-Isomer, TV1022. Ann. N.Y. Acad. Sci. 2001, 939, 320&#x2013;329. 10.1111/j.1749-6632.2001.tb03641.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2001.tb03641.x</ArticleId><ArticleId IdType="pubmed">11462787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X. X.; Wang Y.; Qin Z. H. Molecular Mechanisms Of Excitotoxicity And Their Relevance To Pathogenesis Of Neurodegenerative Diseases. Acta Pharmacol. Sin. 2009, 30 (4), 379&#x2013;387. 10.1038/aps.2009.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2009.24</ArticleId><ArticleId IdType="pmc">PMC4002277</ArticleId><ArticleId IdType="pubmed">19343058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala G.; Arosio A.; Conti E.; Beretta S.; Lunetta C.; Riva N.; Ferrarese C.; Tremolizzo L. Riluzole Selective Antioxidant Effects In Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes. Clin. Psychopharmacol. Neurosci. 2019, 17 (3), 438&#x2013;442. 10.9758/cpn.2019.17.3.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2019.17.3.438</ArticleId><ArticleId IdType="pmc">PMC6705104</ArticleId><ArticleId IdType="pubmed">31352711</ArticleId></ArticleIdList></Reference><Reference><Citation>Prati F.; Cavalli A.; Bolognesi M. Navigating The Chemical Space Of Multitarget-Directed Ligands: From Hybrids To Fragments In Alzheimer&#x2019;s Disease. Molecules 2016, 21 (4), 466.10.3390/molecules21040466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules21040466</ArticleId><ArticleId IdType="pmc">PMC6273289</ArticleId><ArticleId IdType="pubmed">27070562</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney J. B.; Rattray M.; Pugh V.; Powell L. A. Riluzole-Triazole Hybrids As Novel Chemical Probes For Neuroprotection In Amyotrophic Lateral Sclerosis. ACS Med. Chem. Lett. 2018, 9 (6), 552&#x2013;556. 10.1021/acsmedchemlett.8b00103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.8b00103</ArticleId><ArticleId IdType="pmc">PMC6004570</ArticleId><ArticleId IdType="pubmed">29937981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignani S.; Majoral J. P.; Desaphy J. F.; Lentini G. From Riluzole To Dexpramipexole Via Substituted-Benzothiazole Derivatives For Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies. Molecules 2020, 25 (15), 332010.3390/molecules25153320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25153320</ArticleId><ArticleId IdType="pmc">PMC7435757</ArticleId><ArticleId IdType="pubmed">32707914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Am O.; Amit T.; Youdim M. B.; Weinreb O. Neuroprotective And Neurorestorative Potential Of Propargylamine Derivatives In Ageing: Focus On Mitochondrial Targets. J. Neural Transm. 2016, 123 (2), 125&#x2013;135. 10.1007/s00702-015-1395-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-015-1395-3</ArticleId><ArticleId IdType="pubmed">25859841</ArticleId></ArticleIdList></Reference><Reference><Citation>Wager T. T.; Hou X.; Verhoest P. R.; Villalobos A. Moving Beyond Rules: The Development Of A Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment Of Druglike Properties. ACS Chem. Neurosci. 2010, 1 (6), 435&#x2013;449. 10.1021/cn100008c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn100008c</ArticleId><ArticleId IdType="pmc">PMC3368654</ArticleId><ArticleId IdType="pubmed">22778837</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan A. D.; Luo C.; Reitz A. B. Efficient Conversion Of Substituted Aryl Thioureas To 2-Aminobenzothiazoles Using Benzyltrimethylammonium Tribromide. J. Org. Chem. 2003, 68 (22), 8693&#x2013;8696. 10.1021/jo0349431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jo0349431</ArticleId><ArticleId IdType="pubmed">14575503</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O.; Bordoni M.; Dufruca L.; Diamanti L.; Sproviero D.; Trotti R.; Bernuzzi S.; La Salvia S.; Gagliardi S.; Ceroni M.; Cereda C. Lymphoblastoid Cell Lines As A Model To Understand Amyotrophic Lateral Sclerosis Disease Mechanisms. Dis. Models Mech. 2018, 11 (3), dmm03162510.1242/dmm.031625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.031625</ArticleId><ArticleId IdType="pmc">PMC5897724</ArticleId><ArticleId IdType="pubmed">29419416</ArticleId></ArticleIdList></Reference><Reference><Citation>Di L.; Kerns E. H.; Fan K.; Mcconnell O. J.; Carter G. T. High Throughput Artificial Membrane Permeability Assay For Blood-Brain Barrier. Eur. J. Med. Chem. 2003, 38 (3), 223&#x2013;232. 10.1016/S0223-5234(03)00012-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0223-5234(03)00012-6</ArticleId><ArticleId IdType="pubmed">12667689</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland J. M.; Moore D.; Wang Y.; Walsh M.; Mozaffar T.; Elman L.; Nations S. P.; Mitsumoto H.; Fernandes J. A.; Saperstein D.; Hayat G.; Herbelin L.; Karam C.; Katz J.; Wilkins H. M.; Agbas A.; Swerdlow R. H.; Santella R. M.; Dimachkie M. M.; Barohn R. J. Rasagiline For Amyotrophic Lateral Sclerosis: A Randomized, Controlled Trial. Muscle Nerve 2019, 59 (2), 201&#x2013;207. 10.1002/mus.26335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26335</ArticleId><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel S.; Weinreb O.; Amit T.; Youdim M. B. Mechanism Of Neuroprotective Action Of The Anti-Parkinson Drug Rasagiline And Its Derivatives. Brain Res. Rev. 2005, 48 (2), 379&#x2013;387. 10.1016/j.brainresrev.2004.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2004.12.027</ArticleId><ArticleId IdType="pubmed">15850677</ArticleId></ArticleIdList></Reference><Reference><Citation>Binda C.; Hub&#xe1;lek F.; Li M.; Herzig Y.; Sterling J.; Edmondson D. E.; Mattevi A. Crystal Structures Of Monoamine Oxidase B In Complex With Four Inhibitors Of The N-Propargylaminoindan Class. J. Med. Chem. 2004, 47 (7), 1767&#x2013;1774. 10.1021/jm031087c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm031087c</ArticleId><ArticleId IdType="pubmed">15027868</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado I. G.; Redondo M.; Bello M. L.; Perez C.; Liachko N. F.; Kraemer B. C.; Miguel L.; Lecourtois M.; Gil C.; Martinez A.; Perez D. I. Protein Kinase CK-1 Inhibitors As New Potential Drugs For Amyotrophic Lateral Sclerosis. J. Med. Chem. 2014, 57 (6), 2755&#x2013;2772. 10.1021/jm500065f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm500065f</ArticleId><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Gonz&#xe1;lez L.; Rodr&#xed;guez-Cueto C.; Cabezudo D.; Bartolom&#xe9; F.; Andr&#xe9;s-Benito P.; Ferrer I.; Gil C.; Mart&#xed;n-Requero &#xc1;.; Fern&#xe1;ndez-Ruiz J.; Mart&#xed;nez A.; de Lago E. Motor Neuron Preservation And Decrease Of In Vivo TDP-43 Phosphorylation By Protein CK-1&#x3b4; Kinase Inhibitor Treatment. Sci. Rep. 2020, 10 (1), 4449.10.1038/s41598-020-61265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissaro M.; Federico S.; Salmaso V.; Sturlese M.; Spalluto G.; Moro S. Targeting Protein Kinase CK1&#x3b4; With Riluzole: Could It Be One Of The Possible Missing Bricks To Interpret Its Effect In The Treatment Of ALS From A Molecular Point Of View?. ChemMedChem 2018, 13 (24), 2601&#x2013;2605. 10.1002/cmdc.201800632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201800632</ArticleId><ArticleId IdType="pubmed">30359484</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S. P.; Duffy L. M.; Shaw P. J.; Grierson A. J. Altered Age-Related Changes In Bioenergetic Properties And Mitochondrial Morphology In Fibroblasts From Sporadic Amyotrophic Lateral Sclerosis Patients. Neurobiol. Aging 2015, 36 (10), 2893&#x2013;2903. 10.1016/j.neurobiolaging.2015.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.07.013</ArticleId><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I.; Porras G.; Arribas-Blazquez M.; Maestro I.; Borrego-Hernandez D.; Boya P.; Cerdan S.; Garcia-Redondo A.; Martinez A.; Martin-Requero A. Molecular Alterations In Sporadic And SOD1-ALS Immortalized Lymphocytes: Towards A Personalized Therapy. Int. J. Mol. Sci. 2021, 22 (6), 300710.3390/ijms22063007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063007</ArticleId><ArticleId IdType="pmc">PMC8000750</ArticleId><ArticleId IdType="pubmed">33809456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Oliveira T.; Silva D. F.; Segura L.; Baldeiras I.; Marques R.; Rosenstock T.; Oliveira P. J.; Silva F. S. G. Redox Profiles Of Amyotrophic Lateral Sclerosis Lymphoblasts With Or Without Known SOD1 Mutations. Eur. J. Clin. Invest. 2022, 10.1111/eci.13798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13798</ArticleId><ArticleId IdType="pubmed">35467758</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva F. S. G.; Starostina I. G.; Ivanova V. V.; Rizvanov A. A.; Oliveira P. J.; Pereira S. P. Determination Of Metabolic Viability And Cell Mass Using A Tandem Resazurin/Sulforhodamine B Assay. Curr. Protoc. Toxicol. 2016, 68, 2.24.1&#x2013;22.24.15. 10.1002/cptx.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cptx.1</ArticleId><ArticleId IdType="pubmed">27145111</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi H.; Maruyama W.; Akao Y.; Takahashi T.; Iwasa K.; Youdim M. B.; Naoi M. N-Propargylamine Protects SH-SY5Y Cells From Apoptosis Induced By An Endogenous Neurotoxin, N-Methyl-(R)-Salsolinol, Through Stabilization Of Mitochondrial Membrane And Induction Of Anti-Apoptotic Bcl-2. J. Neural Transm. 2006, 113 (1), 21&#x2013;32. 10.1007/s00702-005-0299-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-005-0299-z</ArticleId><ArticleId IdType="pubmed">15843867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatton W.; Chalmers-Redman R.; Tatton N. Neuroprotection By Deprenyl And Other Propargylamines: Glyceraldehyde-3-Phosphate Dehydrogenase Rather Than Monoamine Oxidase B. J. Neural Transm. 2003, 110 (5), 509&#x2013;515. 10.1007/s00702-002-0827-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-002-0827-z</ArticleId><ArticleId IdType="pubmed">12721812</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh J. Y.; Kim D. K.; Hwang J. Y.; Kim Y. H.; Seo J. H. Antioxidative And Proapoptotic Effects Of Riluzole On Cultured Cortical Neurons. J. Neurochem. 1999, 72 (2), 716&#x2013;723. 10.1046/j.1471-4159.1999.0720716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0720716.x</ArticleId><ArticleId IdType="pubmed">9930745</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzini M.; Chelini A.; Mancini A.; Cappelli A.; Frosini M.; Ricci L.; Valoti M.; Magistretti J.; Castelli L.; Giordani A.; Makovec F.; Vomero S. Synthesis And Biological Evaluation Of Amidine, Guanidine, And Thiourea Derivatives Of 2-Amino(6-Trifluoromethoxy)Benzothiazole As Neuroprotective Agents Potentially Useful In Brain Diseases. J. Med. Chem. 2010, 53 (2), 734&#x2013;744. 10.1021/jm901375r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm901375r</ArticleId><ArticleId IdType="pubmed">19950903</ArticleId></ArticleIdList></Reference><Reference><Citation>Criddle D. N.; Gillies S.; Baumgartner-Wilson H. K.; Jaffar M.; Chinje E. C.; Passmore S.; Chvanov M.; Barrow S.; Gerasimenko O. V.; Tepikin A. V.; Sutton R.; Petersen O. H. Menadione-Induced Reactive Oxygen Species Generation Via Redox Cycling Promotes Apoptosis Of Murine Pancreatic Acinar Cells. J. Biol. Chem. 2006, 281 (52), 40485&#x2013;40492. 10.1074/jbc.M607704200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M607704200</ArticleId><ArticleId IdType="pubmed">17088248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala G.; Arosio A.; Conti E.; Beretta S.; Lunetta C.; Riva N.; Ferrarese C.; Tremolizzo L. Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes. Clin. Psychopharmacol. Neurosci. 2019, 17 (3), 438&#x2013;442. 10.9758/cpn.2019.17.3.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2019.17.3.438</ArticleId><ArticleId IdType="pmc">PMC6705104</ArticleId><ArticleId IdType="pubmed">31352711</ArticleId></ArticleIdList></Reference><Reference><Citation>Dessi F.; Benari Y.; Charriautmarlangue C. Riluzole Prevents Anoxic Injury In Cultured Cerebellar Granule Neurons. Eur. J. Pharmacol. 1993, 250 (2), 325&#x2013;328. 10.1016/0014-2999(93)90398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(93)90398-2</ArticleId><ArticleId IdType="pubmed">8112389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D.; Ziv N.; Finberg J. Characterization Of The Neuroprotective Activity Of Rasagiline In Cerebellar Granule Cells. Neuropharmacology 2005, 48 (3), 406&#x2013;416. 10.1016/j.neuropharm.2004.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2004.10.016</ArticleId><ArticleId IdType="pubmed">15721173</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.; Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front. Immunol. 2017, 8, 100510.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.; Beers D.; Zhao W.; Appel S. Microglia In ALS: The Good, The Bad, And The Resting. J. NeuroImmune Pharmacol. 2009, 4 (4), 389&#x2013;398. 10.1007/s11481-009-9171-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-009-9171-5</ArticleId><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Trudler D.; Weinreb O.; Mandel S. A.; Youdim M. B.; Frenkel D. DJ-1 Deficiency Triggers Microglia Sensitivity To Dopamine Toward A Pro-Inflammatory Phenotype That Is Attenuated By Rasagiline. J. Neurochem. 2014, 129 (3), 434&#x2013;447. 10.1111/jnc.12633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12633</ArticleId><ArticleId IdType="pubmed">24355073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanzadeh K.; Roshangar L.; Habibi-asl B.; Farajnia S.; Izadpanah E.; Nemati M.; Arasteh M.; Mohammadi S. Riluzole Prevents Morphine-Induced Apoptosis In Rat Cerebral Cortex. Pharmacol. Rep. 2011, 63 (3), 697&#x2013;707. 10.1016/S1734-1140(11)70581-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(11)70581-3</ArticleId><ArticleId IdType="pubmed">21857080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>